Investment Thesis
Celldex Therapeutics is a pre-revenue biotech company in severe financial distress with $1.5M in revenue (down 78% YoY), massive operating losses of $287.4M, and negative free cash flow of $213.7M. The company is burning cash at an unsustainable rate with only $28.9M in liquidity against $210.9M in negative operating cash flow, indicating critical runway concerns despite strong balance sheet equity.
Strengths
- Strong balance sheet with $527.2M in stockholders' equity providing strategic cushion
- Minimal debt burden with zero long-term debt and clean capital structure
- Adequate current ratio of 10.49x indicating short-term liquidity despite cash burn
Risks
- Catastrophic cash burn of $210.9M from operations with only $28.9M cash remaining; estimated runway of less than 2 months
- Revenue collapse of 78% YoY to $1.5M suggests failed commercialization or terminated programs
- Unsustainable negative margins with -18,600% operating margin and -16,748% net margin indicating core business model failure
Key Metrics to Watch
- Cash burn rate and quarterly cash position relative to remaining runway
- Revenue stabilization or recovery from current $1.5M annualized rate
- Pipeline milestone announcements and clinical trial progression for biotech programs
Financial Metrics
Revenue
1.5M
Net Income
-258.8M
EPS (Diluted)
$-3.90
Free Cash Flow
-213.7M
Total Assets
583.0M
Cash
28.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-18,599.8%
Net Margin
-16,748.0%
ROE
-49.1%
ROA
-44.4%
FCF Margin
-13,829.1%
Balance Sheet & Liquidity
Current Ratio
10.49x
Quick Ratio
10.49x
Debt/Equity
0.00x
Debt/Assets
9.6%
Interest Coverage
-310.00x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T11:36:11.556391 |
Data as of: 2025-12-31 |
Powered by Claude AI